Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Revenue of Insmed Incorporated (INSM)
Revenue in 2023 (TTM): $305.21 M
According to Insmed Incorporated's latest financial reports the company's current revenue (TTM) is $305.21 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Insmed Incorporated
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $305.21 M | $239.64 M | $-654,739,000 | $-747,012,000 | $-749,567,000 |
| 2022 | $245.36 M | $190.23 M | $-429,438,000 | $-480,151,000 | $-481,534,000 |
| 2021 | $188.46 M | $144.31 M | $-375,094,000 | $-436,412,000 | $-434,654,000 |
| 2020 | $164.41 M | $124.54 M | $-250,371,000 | $-292,688,000 | $-294,090,000 |
| 2019 | $136.47 M | $112.26 M | $-215,674,000 | $-253,560,000 | $-254,337,000 |
| 2018 | $9.84 M | $7.41 M | $-293,778,000 | $-324,076,000 | $-324,277,000 |
| 2017 | $ | $-2,901,000 | $-184,095,000 | $-192,921,000 | $-192,649,000 |
| 2016 | $ | $-2,438,000 | $-170,239,000 | $-176,175,000 | $-176,273,000 |
| 2015 | $ | $-1,982,000 | $-115,283,000 | $-120,154,000 | $-118,183,000 |
| 2014 | $11.5 M | $-22,034,999 | $-86,093,000 | $-89,581,000 | $-79,159,000 |
| 2013 | $11.5 M | $-18,144,000 | $-54,202,000 | $-57,294,000 | $-56,073,000 |
| 2012 | $ | $-21,369,000 | $-40,050,000 | $-41,374,000 | $-41,374,000 |
| 2011 | $4.42 M | $4.42 M | $-59,311,000 | $-59,664,000 | $-59,664,000 |
| 2010 | $6.92 M | $6.92 M | $-6,193,000 | $-6,356,000 | $-6,434,000 |
| 2009 | $10.37 M | $10.37 M | $120.32 M | $118.83 M | $118.35 M |
| 2008 | $11.7 M | $11.7 M | $-13,368,000 | $-15,667,000 | $-15,667,000 |
| 2007 | $7.53 M | $6.95 M | $-18,874,000 | $-19,962,000 | $-19,962,000 |
| 2006 | $991 K | $-499,000 | $-49,067,000 | $-56,139,000 | $-56,139,000 |
| 2005 | $131 K | $131 K | $-13,785,000 | $-40,929,000 | $-40,929,000 |
| 2004 | $137 K | $137 K | $-27,169,000 | $-36,417,000 | $-27,203,000 |
| 2003 | $150 K | $150 K | $-10,490,000 | $-10,298,000 | $-10,298,000 |
| 2002 | $1.96 M | $1.96 M | $-34,145,000 | $-36,417,000 | $-36,417,000 |
| 2001 | $296 K | $296 K | $-38,644,000 | $-37,169,000 | $-37,169,000 |
| 2000 | $60 K | $60 K | $-30,312,000 | $-79,662,000 | $-79,862,000 |
| 1999 | $663.16 K | $749.74 K | $-8,043,000 | $ | $-7,792,684 |